Wasn't it stated at last agm that the collaboration with takeda...

First 19 Last

Share
Profile

Follow
m123456

1,334 Posts.

22

31/10/18

09:48

Post #: 36326945
Share

Originally posted by pivalde ↑

m123456, IMO Takeda co-operation takes much more time than just over 1y. It is an animal study or several of them, I suppose and when we get to phase 2 with PBT434 it is a very good thing to know more about the gastrointestinal dysfunction in PD (or MSA) and if PBT434 will help these symptoms and how. The paper below tells more about these gastro problems. PD is a system disease and we can talk today about gastroparesis but understanding of it is still not perfect.

Curr Treat Options Neurol. 2018 Oct 25;20(12):54. doi: 10.1007/s11940-018-0539-9.
Gastrointestinal Dysfunction in Parkinson's Disease.

Pfeiffer RF¹.
Author information

Abstract

PURPOSE OF REVIEW:

During the past 25 years, there has been an explosion of information regarding the occurrence of gastrointestinal dysfunction in Parkinson's disease. In this review, the clinical features of gastrointestinal dysfunction in Parkinson's disease will be described and information regarding the potential role of the enteric nervous system and the gut microbiome in the genesis of Parkinson's disease will be addressed.
RECENT FINDINGS:

Recognition is growing regarding the role that gastroparesis and small intestinal dysfunction may play in Parkinson's disease, especially with regard to erratic responses to anti-Parkinson medication. The presence of enteric nervous system involvement in Parkinson's disease is now well established, but whether the enteric nervous system is the starting point for Parkinson's disease pathology remains a source of debate. The potential role of the gut microbiome also is beginning to emerge. Gastrointestinal dysfunction is a prominent nonmotor feature of Parkinson's disease and dysfunction can be found along the entire length of the gastrointestinal tract. The enteric nervous system is clearly involved in Parkinson's disease. Whether it is the initial source of pathology is still a source of controversy. There also is growing recognition of the role that the gut microbiome may play in Parkinson's disease, but much more research is needed to fully assess this aspect of the disorder.

Expand

Wasn't it stated at last agm that the collaboration with takeda was over? Please correct me if Im wrong but that's what I vaguely recall and I remember being suprised how fast it was and there was nothing to report

PBT Price at posting: 4.4¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched stocks for Week 48, 2024

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 11 more messages in this thread...

First 19 Last

Add PBT (ASX) to my watchlist

Wasn't it stated at last agm that the collaboration with takeda...

Top Stories

HotCopper Highlights: Your most watched stocks for Week 48, 2024

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up